Skip to main content
Erschienen in: Calcified Tissue International 3/2011

01.09.2011 | Original Research

MKP-1 Knockout Does not Prevent Glucocorticoid-Induced Bone Disease in Mice

verfasst von: Maria M. Conradie, Andrew C. B. Cato, William F. Ferris, Heidi de Wet, Kay Horsch, Stephen Hough

Erschienen in: Calcified Tissue International | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Glucocorticoid-induced osteoporosis (GCOP) is predominantly caused by inhibition of bone formation, resulting from a decrease in osteoblast numbers. Employing mouse (MBA-15.4) and human (MG-63) osteoblast cell lines, we previously found that the glucocorticoid (GC) dexamethasone (Dex) inhibits cellular proliferation as well as activation of the MAPK/ERK signaling pathway, essential for mitogenesis in these cells, and that both these effects could be reversed by the protein tyrosine phosphatase (PTP) inhibitor vanadate. In a rat model of GCOP, the GC-induced changes in bone formation, mass, and strength could be prevented by vanadate cotreatment, suggesting that the GC effects on bone were mediated by one or more PTPs. Employing phosphatase inhibitors, qRT-PCR, Western blotting, and overexpression/knockdown experiments, we concluded that MKP-1 was upregulated by Dex, that this correlated with the dephosphorylation of ERK, and that it largely mediated the in vitro effects of GCs on bone. To confirm the pivotal role of MKP-1 in vivo, we investigated the effects of the GC methylprednisolone on the quantitative bone histology of wild-type (WT) and MKP-1 homozygous knockout (MKP-1−/−) mice. In WT mice, static bone histology revealed that GC administration for 28 days decreased osteoid surfaces, volumes, and osteoblast numbers. Dynamic histology, following time-spaced tetracycline labeling, confirmed a significant GC-induced reduction in osteoblast appositional rate and bone formation rate. However, identical results were obtained in MKP-1 knockout mice, suggesting that in these animals upregulation of MKP-1 by GCs cannot be regarded as the sole mediator of the GC effects on bone.
Literatur
1.
Zurück zum Zitat Canalis E, Mazziotti G, Giustina A, Bilezekian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRef Canalis E, Mazziotti G, Giustina A, Bilezekian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRef
2.
Zurück zum Zitat Weinstein RS (2008) Glucocorticoid-induced osteoporosis. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. ASBMR, Washington, pp 267–272CrossRef Weinstein RS (2008) Glucocorticoid-induced osteoporosis. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. ASBMR, Washington, pp 267–272CrossRef
3.
Zurück zum Zitat Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137PubMedCrossRef Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137PubMedCrossRef
4.
Zurück zum Zitat O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induces their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841PubMedCrossRef O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induces their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841PubMedCrossRef
5.
Zurück zum Zitat Engelbrecht Y, de Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley A (2003) Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 144:412–422PubMedCrossRef Engelbrecht Y, de Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley A (2003) Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 144:412–422PubMedCrossRef
6.
Zurück zum Zitat Horsch K, de Wet H, Schuurmans MM, Allie-Reid F, Cato AC, Cunningham J, Burrin JM, Hough FS, Hulley PA (2007) Mitogen-activated protein kinase phosphatase-1/dual specificity phosphatase-1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrinol 21:2929–2940PubMedCrossRef Horsch K, de Wet H, Schuurmans MM, Allie-Reid F, Cato AC, Cunningham J, Burrin JM, Hough FS, Hulley PA (2007) Mitogen-activated protein kinase phosphatase-1/dual specificity phosphatase-1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrinol 21:2929–2940PubMedCrossRef
7.
Zurück zum Zitat Hulley PA, Gordon F, Hough FS (1998) Inhibition of MAPK activity and proliferation of an early osteoblast cell line (MBA-15.4) by dexamethasone: role of protein phosphatases. Endocrinology 139:2423–2431PubMedCrossRef Hulley PA, Gordon F, Hough FS (1998) Inhibition of MAPK activity and proliferation of an early osteoblast cell line (MBA-15.4) by dexamethasone: role of protein phosphatases. Endocrinology 139:2423–2431PubMedCrossRef
8.
Zurück zum Zitat Hulley PA, Conradie MM, Langeveldt CR, Hough FS (2002) Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. Bone 31:220–229PubMedCrossRef Hulley PA, Conradie MM, Langeveldt CR, Hough FS (2002) Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. Bone 31:220–229PubMedCrossRef
9.
Zurück zum Zitat Conradie MM, de Wet H, Kotze DD, Burrin JM, Hough FS, Hulley PA (2007) Vanadate prevents glucocorticoid-induced apoptosis of osteoblasts in vitro and osteocytes in vivo. J Endocrinol 195:229–240PubMedCrossRef Conradie MM, de Wet H, Kotze DD, Burrin JM, Hough FS, Hulley PA (2007) Vanadate prevents glucocorticoid-induced apoptosis of osteoblasts in vitro and osteocytes in vivo. J Endocrinol 195:229–240PubMedCrossRef
10.
Zurück zum Zitat Boutros T, Chevet E, Metrakos P (2008) Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death and cancer. Pharmacol Rev 60:261–310PubMedCrossRef Boutros T, Chevet E, Metrakos P (2008) Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death and cancer. Pharmacol Rev 60:261–310PubMedCrossRef
11.
Zurück zum Zitat Patterson KI, Brummer T, O’Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475–489PubMed Patterson KI, Brummer T, O’Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475–489PubMed
12.
Zurück zum Zitat Farooq A, Zhou M (2004) Structure and regulation of MAPK phosphatases. Cell Signal 16:769–779PubMedCrossRef Farooq A, Zhou M (2004) Structure and regulation of MAPK phosphatases. Cell Signal 16:769–779PubMedCrossRef
13.
Zurück zum Zitat Hendriks WJAJ, Elson A, Harroch S, Stoker AW (2008) Protein tyrosine phosphatases: functional inferences from mouse models and human disease. FEMS J 275:816–830 Hendriks WJAJ, Elson A, Harroch S, Stoker AW (2008) Protein tyrosine phosphatases: functional inferences from mouse models and human disease. FEMS J 275:816–830
14.
Zurück zum Zitat Goldner JA (1938) A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14:237–242PubMed Goldner JA (1938) A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14:237–242PubMed
15.
Zurück zum Zitat Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef
16.
Zurück zum Zitat Ogawa A, Johnson JH, Ohneda M, McAllister CT, Inman L, Alam T, Unger RH (1992) Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest 90:497–504PubMedCrossRef Ogawa A, Johnson JH, Ohneda M, McAllister CT, Inman L, Alam T, Unger RH (1992) Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest 90:497–504PubMedCrossRef
17.
Zurück zum Zitat Bogoyevitch MA, Court NW (2004) Counting on mitogen-activated protein kinases—ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 16:1345–1354PubMedCrossRef Bogoyevitch MA, Court NW (2004) Counting on mitogen-activated protein kinases—ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 16:1345–1354PubMedCrossRef
18.
Zurück zum Zitat Murphy LO, Blenis J (2006) MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31:268–275PubMedCrossRef Murphy LO, Blenis J (2006) MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31:268–275PubMedCrossRef
19.
Zurück zum Zitat Marshall CJ (1995) Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179–185PubMedCrossRef Marshall CJ (1995) Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179–185PubMedCrossRef
20.
Zurück zum Zitat Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK (2007) Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 22(7):951–959PubMedCrossRef Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK (2007) Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 22(7):951–959PubMedCrossRef
21.
Zurück zum Zitat Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, Franceschi RT (2000) MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor cbfa1. J Biol Chem 275(6):4453–4459PubMedCrossRef Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, Franceschi RT (2000) MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor cbfa1. J Biol Chem 275(6):4453–4459PubMedCrossRef
22.
Zurück zum Zitat Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E (2003) Multiple signaling pathways converge on the cbfa1/runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res 44:109–116PubMed Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E (2003) Multiple signaling pathways converge on the cbfa1/runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res 44:109–116PubMed
23.
Zurück zum Zitat Ge C, Xiao G, Franceschi RT (2007) Critical role of the extracellular signal-regulated kinase–MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol 176(5):709–718PubMedCrossRef Ge C, Xiao G, Franceschi RT (2007) Critical role of the extracellular signal-regulated kinase–MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol 176(5):709–718PubMedCrossRef
24.
Zurück zum Zitat Higuchi CA, Myoui N, Hashimoto K, Kuriyama K, Yoshioka H, Itoh K (2002) Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 17:1785–1794PubMedCrossRef Higuchi CA, Myoui N, Hashimoto K, Kuriyama K, Yoshioka H, Itoh K (2002) Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 17:1785–1794PubMedCrossRef
25.
Zurück zum Zitat Nakayama KY, Tamura M, Suzawa S, Harada S, Fukumoto S, Kato M, Miyazono, K, Rodan GA, Takeuchi Y, Fujita T (2003) Receptor tyrosine kinases inhibit bone morphogenetic protein-smad responsive promoter activity and differentiation of MC3T3-E1 osteoblast like cells. J Bone Miner Res 18:827–835PubMedCrossRef Nakayama KY, Tamura M, Suzawa S, Harada S, Fukumoto S, Kato M, Miyazono, K, Rodan GA, Takeuchi Y, Fujita T (2003) Receptor tyrosine kinases inhibit bone morphogenetic protein-smad responsive promoter activity and differentiation of MC3T3-E1 osteoblast like cells. J Bone Miner Res 18:827–835PubMedCrossRef
26.
Zurück zum Zitat Datta NS, Chen C, Berry JE, McCauley LK (2005) PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J Bone Miner Res 20(6):1051–1064PubMedCrossRef Datta NS, Chen C, Berry JE, McCauley LK (2005) PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J Bone Miner Res 20(6):1051–1064PubMedCrossRef
27.
Zurück zum Zitat Datta NS, Kolailat R, Fite A, Pettway G, Abou-Samra AB (2010) Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation. Cell Signal 22:457–466PubMedCrossRef Datta NS, Kolailat R, Fite A, Pettway G, Abou-Samra AB (2010) Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation. Cell Signal 22:457–466PubMedCrossRef
28.
Zurück zum Zitat Waterman H, Yarden Y (2001) Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 490:142–152PubMedCrossRef Waterman H, Yarden Y (2001) Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 490:142–152PubMedCrossRef
29.
Zurück zum Zitat Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O’Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68(20):8322–8332PubMedCrossRef Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O’Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68(20):8322–8332PubMedCrossRef
30.
Zurück zum Zitat Langlois WJ, Sasaoka T, Saltiel AR, Olefsky JM (1995) Negative feedback regulation and desensitization of insulin and epidermal growth factor-stimulated p21 ras activation. J Biol Chem 270:25320–25323PubMedCrossRef Langlois WJ, Sasaoka T, Saltiel AR, Olefsky JM (1995) Negative feedback regulation and desensitization of insulin and epidermal growth factor-stimulated p21 ras activation. J Biol Chem 270:25320–25323PubMedCrossRef
31.
Zurück zum Zitat Donovan S, Shannon KM, Bollag G (2002) GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 160:23–45 Donovan S, Shannon KM, Bollag G (2002) GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 160:23–45
32.
Zurück zum Zitat Camps M, Nichols A, Arkinstall S (2000) Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 14:6–16PubMed Camps M, Nichols A, Arkinstall S (2000) Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 14:6–16PubMed
33.
Zurück zum Zitat Dickinson RJ, Keyse SM (2006) Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119:4607–4614PubMedCrossRef Dickinson RJ, Keyse SM (2006) Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119:4607–4614PubMedCrossRef
34.
Zurück zum Zitat Qin L, Li X, Ko J, Partridge NC (2005) Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem 280(4):3104–3111PubMedCrossRef Qin L, Li X, Ko J, Partridge NC (2005) Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem 280(4):3104–3111PubMedCrossRef
35.
Zurück zum Zitat Homme M, Schmitt CP, Mehls O, Schaefer F (2004) Mechanisms of mitogen-activated protein kinase inhibition by parathyroid hormone in osteoblast-like cells. J Am Soc Nephrol 15:2844–2850PubMedCrossRef Homme M, Schmitt CP, Mehls O, Schaefer F (2004) Mechanisms of mitogen-activated protein kinase inhibition by parathyroid hormone in osteoblast-like cells. J Am Soc Nephrol 15:2844–2850PubMedCrossRef
36.
Zurück zum Zitat Aghaloo TL, Pirih FQ, Shi A, Bezouglaia O, Tetradis S (2006) Parathyroid hormone induces mitogen-activated kinase phosphatase 1 in murine osteoblasts primarily through cAMP-protein kinase A signaling. Periodontol 77:21–30CrossRef Aghaloo TL, Pirih FQ, Shi A, Bezouglaia O, Tetradis S (2006) Parathyroid hormone induces mitogen-activated kinase phosphatase 1 in murine osteoblasts primarily through cAMP-protein kinase A signaling. Periodontol 77:21–30CrossRef
37.
Zurück zum Zitat Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR (2006) Anti-inflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203(8):1883–1889PubMedCrossRef Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR (2006) Anti-inflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203(8):1883–1889PubMedCrossRef
38.
Zurück zum Zitat Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R (1996) Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAPkinase activity in ERP/MKP-1 deficient fibroblasts. Oncogene 13(5):925–931PubMed Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R (1996) Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAPkinase activity in ERP/MKP-1 deficient fibroblasts. Oncogene 13(5):925–931PubMed
39.
Zurück zum Zitat Sakaue H, Ogawa W, Nakamura T, Mori T, Nakamura K, Kasuga M (2004) Role of MAPK phosphatase-1 (MKP-1) in adipocyte. J Biol Chem 279(38):39951–39957PubMedCrossRef Sakaue H, Ogawa W, Nakamura T, Mori T, Nakamura K, Kasuga M (2004) Role of MAPK phosphatase-1 (MKP-1) in adipocyte. J Biol Chem 279(38):39951–39957PubMedCrossRef
40.
Zurück zum Zitat Bazuine M, Carlotti F, Tafrechi RS, Hoeben RC, Maassen JA (2004) Mitogen-activated protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 18(7):1697–1707PubMedCrossRef Bazuine M, Carlotti F, Tafrechi RS, Hoeben RC, Maassen JA (2004) Mitogen-activated protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 18(7):1697–1707PubMedCrossRef
41.
Zurück zum Zitat Zhou Y, Ling ED, Dheen ST (2007) Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem 102(3):667–678PubMedCrossRef Zhou Y, Ling ED, Dheen ST (2007) Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem 102(3):667–678PubMedCrossRef
42.
Zurück zum Zitat Fürst R, Schroeder T, Eilken HM, Bubik MF, Kiemer AK, Zahler S, Vollmar AM (2007) MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in human endothelium. FASEB J 21(1):74–80PubMedCrossRef Fürst R, Schroeder T, Eilken HM, Bubik MF, Kiemer AK, Zahler S, Vollmar AM (2007) MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in human endothelium. FASEB J 21(1):74–80PubMedCrossRef
43.
Zurück zum Zitat Maier JV, Brema S, Tuckermann J, Herzer U, Klein M, Stassen M, Moorthy A, Cato AC (2001) Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol 21:2663–2671CrossRef Maier JV, Brema S, Tuckermann J, Herzer U, Klein M, Stassen M, Moorthy A, Cato AC (2001) Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol 21:2663–2671CrossRef
44.
Zurück zum Zitat Kassel O, Sancono A, Krätzschmar J, Kreft B, Stassen M, Cato AC (2001) Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20(24):7108–7116PubMedCrossRef Kassel O, Sancono A, Krätzschmar J, Kreft B, Stassen M, Cato AC (2001) Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20(24):7108–7116PubMedCrossRef
45.
Zurück zum Zitat Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T (2006) Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 176:1899–1907PubMed Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T (2006) Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 176:1899–1907PubMed
46.
Zurück zum Zitat Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman GI, Kim JK, Bennett AM (2006) Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet induced obesity. Cell Metab 4(1):61–73PubMedCrossRef Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman GI, Kim JK, Bennett AM (2006) Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet induced obesity. Cell Metab 4(1):61–73PubMedCrossRef
Metadaten
Titel
MKP-1 Knockout Does not Prevent Glucocorticoid-Induced Bone Disease in Mice
verfasst von
Maria M. Conradie
Andrew C. B. Cato
William F. Ferris
Heidi de Wet
Kay Horsch
Stephen Hough
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Calcified Tissue International / Ausgabe 3/2011
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-011-9509-x

Weitere Artikel der Ausgabe 3/2011

Calcified Tissue International 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.